Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
24.31
+0.40 (1.67%)
Nov 20, 2024, 4:00 PM EST - Market closed
Rigel Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for RIGL stock have an average target of 31.3, with a low estimate of 12.5 and a high estimate of 57. The average target predicts an increase of 28.75% from the current stock price of 24.31.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for RIGL stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Maintains $15 → $23 | Hold | Maintains | $15 → $23 | -5.39% | Nov 14, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $40 → $49 | Strong Buy | Maintains | $40 → $49 | +101.56% | Nov 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +134.47% | Oct 25, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates $15 | Hold | Reiterates | $15 | -38.30% | Sep 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +134.47% | Sep 5, 2024 |
Financial Forecast
Revenue This Year
160.08M
from 115.78M
Increased by 38.26%
Revenue Next Year
198.84M
from 160.08M
Increased by 24.21%
EPS This Year
-0.36
from -1.44
EPS Next Year
0.68
from -0.36
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 173.4M | 226.8M | 277.4M | ||
| Avg | 160.1M | 198.8M | 234.1M | ||
| Low | 142.4M | 172.7M | 209.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 49.7% | 41.7% | 39.5% | ||
| Avg | 38.3% | 24.2% | 17.7% | ||
| Low | 23.0% | 7.9% | 5.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.19 | 1.69 | 3.85 | ||
| Avg | -0.36 | 0.68 | 1.68 | ||
| Low | -0.99 | 0.08 | 0.63 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 468.3% | ||
| Avg | - | - | 147.1% | ||
| Low | - | - | -7.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.